Literature DB >> 15674425

Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells.

M Farahani1, A T Treweeke, C H Toh, K J Till, R J Harris, J C Cawley, M Zuzel, H Chen.   

Abstract

CD154 is an important regulator of chronic lymphocytic leukaemia (CLL)-cell survival. In CLL, high serum levels of VEGF are a feature of advanced disease, and we and others have previously shown that CLL cells produce and secrete this growth factor. Since CD154 stimulates VEGF production in other cell types, and VEGF is known to promote cell survival, we examined whether the cytoprotection of CLL cells by CD154 involves VEGF. We report for the first time that treatment of CLL cells with CD154 results in increased VEGF production and demonstrate involvement of NF-kappaB in this process. Moreover, we show that CD154-induced CLL-cell survival is reduced by anti-VEGF-neutralising antibody and by inhibiting VEGF receptor (VEGFR) signalling with SU5416. However, addition of exogenous VEGF alone or blocking secreted autocrine VEGF had little or no effect on CLL-cell survival. We therefore conclude that CLL-cell cytoprotection in the presence of CD154 requires combined signalling by both CD40 and VEGFR. This combined signalling and resulting cytoprotection were shown to involve NF-kappaB activation and increased survivin production. In conclusion, our findings identify autocrine VEGF as an important mediator of the antiapoptotic effect of CD40 ligation, and thus provide new insights into CLL-cell rescue by CD154 in lymphoreticular tissues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674425     DOI: 10.1038/sj.leu.2403631

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  23 in total

1.  Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Simon Jonas Poll-Wolbeck; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Med       Date:  2011-04-14       Impact factor: 6.354

2.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

Review 3.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

4.  Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells.

Authors:  Grzegorz S Nowakowski; Debabrata Mukhopadhyay; Xiaosheng Wu; Neil E Kay
Journal:  Leuk Res       Date:  2008-04-09       Impact factor: 3.156

5.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

6.  Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.

Authors:  Xavier Badoux; Carlos Bueso-Ramos; David Harris; Ping Li; Zhiming Liu; Jan Burger; Susan O'Brien; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Hum Pathol       Date:  2011-07-05       Impact factor: 3.466

7.  FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.

Authors:  Preetesh Jain; Hun Ju Lee; Wei Qiao; William Wierda; Ohad Benjamini; Jan Burger; Alessandra Ferrajoli; Zeev Estrov; Hagop Kantarjian; Michael Keating; Susan O'Brien
Journal:  Cancer       Date:  2014-07-15       Impact factor: 6.860

8.  Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.

Authors:  Tait Shanafelt; Clive Zent; John Byrd; Charles Erlichman; Betsy Laplant; Asish Ghosh; Timothy Call; Miguel Villalona-Calero; Diane Jelinek; Deborah Bowen; Kristina Laumann; Wenting Wu; Curtis Hanson; Neil Kay
Journal:  Leuk Lymphoma       Date:  2010-11-05

9.  Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects.

Authors:  Margarita Pérez-Casal; Colin Downey; Beatriz Cutillas-Moreno; Mirko Zuzel; Kenji Fukudome; Cheng Hock Toh
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

Review 10.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.